E Fund Management Co. Ltd. Has $925,000 Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

E Fund Management Co. Ltd. decreased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 12.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,609 shares of the biotechnology company’s stock after selling 1,107 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Sarepta Therapeutics were worth $925,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Inceptionr LLC acquired a new position in Sarepta Therapeutics during the 4th quarter worth $1,326,000. Arizona State Retirement System lifted its holdings in Sarepta Therapeutics by 1.6% during the 4th quarter. Arizona State Retirement System now owns 24,890 shares of the biotechnology company’s stock worth $3,026,000 after buying an additional 394 shares in the last quarter. Proficio Capital Partners LLC acquired a new position in Sarepta Therapeutics during the 4th quarter worth $3,829,000. Assetmark Inc. lifted its holdings in Sarepta Therapeutics by 9.6% during the 4th quarter. Assetmark Inc. now owns 42,759 shares of the biotechnology company’s stock worth $5,199,000 after buying an additional 3,734 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its stake in shares of Sarepta Therapeutics by 34.0% in the 4th quarter. Victory Capital Management Inc. now owns 88,808 shares of the biotechnology company’s stock valued at $10,798,000 after purchasing an additional 22,529 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on SRPT shares. Piper Sandler cut their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. Royal Bank of Canada cut their price target on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a research note on Thursday, February 27th. HC Wainwright reissued a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Sarepta Therapeutics in a research note on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.41.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now owns 22,840 shares of the company’s stock, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Price Performance

SRPT stock opened at $103.03 on Friday. The stock has a 50-day moving average price of $114.48 and a two-hundred day moving average price of $121.80. The stock has a market cap of $10.00 billion, a PE ratio of 82.42 and a beta of 0.79. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 1 year low of $99.50 and a 1 year high of $173.25.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.